Erschienen in:
01.03.2010 | Short Communication
Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease
verfasst von:
Tomoya Fukui, Sakiko Otani, Ryuji Hataishi, Shi-Xu Jiang, Yasuto Nishii, Satoshi Igawa, Hisashi Mitsufuji, Masaru Kubota, Masato Katagiri, Noriyuki Masuda
Erschienen in:
Cancer Chemotherapy and Pharmacology
|
Ausgabe 4/2010
Einloggen, um Zugang zu erhalten
Abstract
Small-molecule tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (
EGFR) pathways are used clinically for patients with non-small cell lung cancer (NSCLC). It is well established that somatic mutations in the kinase domain of the
EGFR (Lynch et al. in N Engl J Med 350:2129–2139,
2004; Paez et al. in Science 304:1497–1500,
2004) are strongly associated with the tumor response and clinical outcomes in patients with NSCLC receiving EGFR-TKIs (Mitsudomi and Yatabe in Cancer Sci 98:1817–1824,
2007). Although the most common adverse events are skin rash and diarrhea, the most serious adverse effect reported is drug-related interstitial lung disease (ILD) (Inoue et al. in Lancet 361:137–139,
2003; Ando et al. in J Clin Oncol 24:2549–2556,
2006). The precise mechanism underlying the development of drug-related ILD remains unknown. Here, we describe a case of
EGFR-mutant NSCLC who was rechallenged with the small-molecule
EGFR antagonist erlotinib after developing gefitinib-related ILD.